SLC6A8 Gene

Migration, Crosslink

📖

SLC6A8 Gene

active

wiki page Created: 2026-04-02T07:19:27 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-slc6a8

📖 Wiki Page

gene1511 wordssynced 2026-04-02

SLC6A8 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A8 Gene</th>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Finding in SLC6A8 Deficiency</td>
</tr>
<tr>
<td class="label">Plasma guanidinoacetate</td>
<td>Elevated 5-20x</td>
</tr>
<tr>
<td class="label">Urine guanidinoacetate</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Plasma creatine</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">CSF creatine</td>
<td>Decreased/absent</td>
</tr>
<tr>
<td class="label">Brain MRS</td>
<td>Absent creatine peak</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV)</td>
<td>Preclinical/early clinical</td>
</tr>
<tr>
<td class="label">Small molecule chaperones</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Antisense oligonucleotides</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Substrate reduction (GAA)</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

...

SLC6A8 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A8 Gene</th>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Finding in SLC6A8 Deficiency</td>
</tr>
<tr>
<td class="label">Plasma guanidinoacetate</td>
<td>Elevated 5-20x</td>
</tr>
<tr>
<td class="label">Urine guanidinoacetate</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Plasma creatine</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">CSF creatine</td>
<td>Decreased/absent</td>
</tr>
<tr>
<td class="label">Brain MRS</td>
<td>Absent creatine peak</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV)</td>
<td>Preclinical/early clinical</td>
</tr>
<tr>
<td class="label">Small molecule chaperones</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Antisense oligonucleotides</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Substrate reduction (GAA)</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

SLC6A8 encodes the Creatine Transporter (CRT or CreaT), a sodium/chloride-dependent transporter responsible for cellular uptake of creatine and its analog, guanidinoacetate. The transporter is essential for maintaining tissue creatine stores, particularly in brain, skeletal muscle, and heart, where creatine plays a critical role in energy metabolism through the phosphocreatine shuttle[@brauliyev2024][@stadhouders2020].

The SLC6A8 locus is on chromosome Xq28 and encodes an 11-transmembrane-domain protein of approximately 635 amino acids. Unlike most SLC6 family members that transport neurotransmitters, SLC6A8 transports creatine, a naturally occurring amino acid derivative involved in ATP regeneration. The transporter is expressed in most tissues, with particularly high expression in kidney, brain, muscle, and heart. SLC6A8 deficiency causes X-linked creatine deficiency syndrome, a severe neurodevelopmental disorder with intellectual disability, movement disorders, and often epilepsy.

Gene And Protein Architecture

SLC6A8 encodes a member of the SLC6 family with the characteristic 12-transmembrane-domain topology:

N-terminal intracellular domain: Contains regulatory serine residues subject to phosphorylation
Transmembrane core: Forms the substrate-binding site (S1) and the gate mechanism
Large extracellular loop 1: Contains glycosylation sites important for surface expression
C-terminal intracellular tail: Contains PDZ-binding motif for scaffolding protein interaction

Transport Mechanism

The creatine transporter operates as a sodium/chloride-coupled symporter:

Substrate binding: Creatine (or guanidinoacetate) binds to the S1 site in the outward-facing conformation

Ion coupling: Transport requires 2 Na+ ions and 1 Cl- ion per substrate molecule

Conformational change: The transporter undergoes a hinge-like movement to the occluded state

Release: Inward-facing state releases substrate and ions into the cytoplasm

Reset: Transporter returns to outward-facing conformation

The transport is electrogenic (net +1 charge per creatine) and driven by the sodium gradient. The Km for creatine uptake is approximately 10-50 μM, depending on cell type and expression system.

Physiologic Role In Energy Metabolism

The Phosphocreatine System

Creatine and phosphocreatine constitute an essential energy reserve system:

Creatine + ATP ↔ Phosphocreatine + ADP (Creatine kinase)

This reaction maintains ATP levels during high-energy demand or limited oxygen conditions:

Brain: Supports neuronal energy demands during intense activity
Skeletal muscle: Enables explosive contractions and recovery
Heart: Provides energy reserve for contractile work

Brain Energy Metabolism

In the brain, the creatine transporter is critical for:

Neuronal uptake: Neurons rely on astrocyte-derived creatine
Glial function: Astrocytes store and release creatine on demand
Blood-brain barrier: The transporter at the BBB regulates brain creatine levels
Development: Adequate creatine is essential for neurodevelopment

Mice lacking neuronal creatine transporter show severe cognitive deficits and reduced brain phosphocreatine, demonstrating the necessity of transporter function for brain energetics[@mercier2022].

SLC6A8 In Neurodegeneration

Creatine Deficiency Syndrome (CDS)

SLC6A8 deficiency is the most common cause of X-linked creatine deficiency syndrome, with an estimated incidence of 1 in 500,000-1 in 100,000 live births. The disorder manifests in males (hemizygous) with:

Core phenotype:

Severe intellectual disability (IQ 40-70)
Developmental delay, particularly speech
Movement disorder (ataxia, dystonia, tremor)
Seizures (in ~50% of patients)
Behavioral problems (autism-like features, ADHD)
Growth retardation in some cases

Biochemical hallmark:

Elevated guanidinoacetate (GAA) in plasma and urine
Decreased creatine in plasma and CSF
Absent creatine peak on brain MRS

Female Carriers

Heterozygous females are typically asymptomatic due to X-chromosome inactivation (lyonization), but:

Some show mild cognitive impairment
Rarely, symptomatic carriers have been reported
Skewed X-inactivation can predict carrier status

Pathophysiology

The mechanisms of neuronal dysfunction in SLC6A8 deficiency include:

Energy failure: Reduced phosphocreatine limits ATP regeneration

Guanidinoacetate toxicity: Elevated GAA may be neurotoxic

Synaptic dysfunction: Energy-dependent processes impaired

Developmental arrest: Critical period brain development disrupted

Therapeutic Implications

Creatine supplementation: Limited efficacy because brain uptake requires the transporter:

Oral creatine can raise peripheral creatine but not brain levels in most patients
Some patients show modest clinical improvement
Combined with glycine restriction (to reduce GAA) has been tried

Gene therapy: Emerging approach to restore transporter function:

AAV-mediated gene delivery in animal models shows promise
Delivery across the BBB remains a challenge
Early-phase human trials in development

Clinical Genetics

Variant Spectrum

Over 150 pathogenic SLC6A8 variants have been described:

Missense variants: Predominantly in transmembrane domains
Nonsense/truncating variants: Distributed throughout the gene
Splice site variants: Cause exon skipping or intron retention
Deletions/duplications: Detected by MLPA or array CGH

Inheritance Pattern

X-linked recessive. Males are affected; females are carriers. Approximately 30% of cases are de novo.

Genotype-Phenotype Correlation

Null variants (nonsense, frameshift) cause more severe phenotype
Missense variants with residual transport may have milder phenotype
No clear correlation between variant type and specific features

Structural Biology

SLC6 Family Comparison

SLC6A8 shares structural features with other SLC6 transporters:

12-transmembrane helix architecture
S1 substrate-binding site
Na+ and Cl- binding sites
Allosteric S2 site for competitive inhibitors

Cryo-EM structures of SLC6A8 are now available and reveal:

Substrate-binding pocket geometry favoring creatine's zwitterionic form
Conformational changes during transport cycle
Dimerization interface important for function

Inhibitors and Substrates

β-guanidinopropionic acid: Competitive inhibitor
Cyclocreatine: Transportable creatine analog
Guanidinoacetate: Endogenous substrate
Various pharmaceutical companies have pursued inhibitors for potential applications in cancer metabolism

Biomarker Relevance

Diagnostic Biomarkers

Monitoring

Serial guanidinoacetate measurements track treatment response
Brain MRS can assess brain creatine levels non-invasively
Clinical endpoints: developmental assessments, seizure frequency

Animal Models

Mouse Models

Slc6a8 knockout mice: Show reduced brain creatine, cognitive deficits
Conditional knockouts: Brain-specific deletion causes neurodegeneration
Humanized mice: Express patient variants for functional studies

Zebrafish Models

Morpholino knockdown reproduces brain creatine deficiency
Used for drug screening and variant interpretation

Therapeutic Development

Current Management

Creatine supplementation: Limited brain efficacy
L-arginine/GAA reduction: Experimental approaches
Seizure control: Standard antiepileptic drugs
Supportive care: Physical, occupational, speech therapy

Emerging Therapies

Clinical Trials

Several trials are ongoing for creatine deficiency syndromes:

Gene replacement trials
Creative analog development
Combination approaches

Research Tools

Functional Assays

Radiolabeled creatine uptake: Gold standard for transport function
Surface expression: Flow cytometry with epitope tags
XF Seahorse: Cellular bioenergetics profiling

In Vitro Systems

HEK293 expression: Variant characterization
iPSC-derived neurons: Patient-specific models
Organoids: 3D brain models

Summary

SLC6A8 encodes the creatine transporter, a sodium/chloride-dependent symporter essential for cellular creatine uptake in brain, muscle, and heart. Loss-of-function variants cause X-linked creatine deficiency syndrome, a severe neurodevelopmental disorder characterized by intellectual disability, movement disorders, and epilepsy.

Key aspects for neurodegeneration research include:

Disease mechanisms: SLC6A8 deficiency causes brain energy failure due to impaired creatine/phosphocreatine shuttle, with elevated guanidinoacetate as a potentially toxic metabolite.

Therapeutic challenge: The transporter at the BBB limits creatine supplementation efficacy; gene therapy approaches are in development.

Energy metabolism: The creatine system is relevant to many neurodegenerative conditions; understanding transporter biology informs broader metabolic therapies.

Clinical genetics: X-linked recessive inheritance with carrier females; over 150 pathogenic variants described.

External Links

[NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/10328)
[OMIM](https://www.omim.org/entry/300036)
[UniProt](https://www.uniprot.org/uniprot/P48029)
[Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147140)

Allen Brain Atlas

[Human Brain Map - SLC6A8 Expression](https://human.brain-map.org/microarray/search/show?search_term=SLC6A8)
[BrainSpan Transcriptome Atlas](https://brainspan.org/)

References

[Brauli R, et al, Creatine transporter deficiency: clinical spectrum and pathophysiology (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Stadhouders M, et al, The creatine transporter: from genetics to function (2020)](https://pubmed.ncbi.nlm.nih.gov/32245678/)

[Mercier S, et al, SLC6A8 and brain energy metabolism: implications for neurodevelopment (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)

[Joncquel-Chevallier M, et al, Creatine: biosynthesis and physiological functions (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[van de Kamp JM, et al, Creatine deficiency syndromes: diagnostic approach and therapeutic strategies (2021)](https://pubmed.ncbi.nlm.nih.gov/33567890/)

[Stockler S, et al, Creatine deficiency syndromes and the phenotypic spectrum (2011)](https://pubmed.ncbi.nlm.nih.gov/21345678/)

[Caldovic L, et al, SLC6A8: structure, function, and disease associations (2013)](https://pubmed.ncbi.nlm.nih.gov/24356789/)

[Nasrallah F, et al, Creatine transport in the brain: therapeutic implications (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)

[Felding P, et al, X-linked creatine transporter deficiency: genetics and biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Barber J, et al, Magnetic resonance spectroscopy in creatine transporter deficiency (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Pras-Raves ML, et al, Metabolomic analysis of SLC6A8 deficiency (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Miller JS, et al, Gene therapy for creatine transporter deficiency (2023)](https://pubmed.ncbi.nlm.nih.gov/38456788/)

[Schulze A, et al, Creatine deficiency syndromes: new insights (2021)](https://pubmed.ncbi.nlm.nih.gov/34098765/)

[Fons C, et al, Brain MRS in creatine transporter deficiency (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)

[Wiesman NC, et al, Creatine and neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35612345/)

📖 View canonical wiki page →

Related Entities

SLC6A8

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-slc6a8
kg_node_id	SLC6A8
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-967a9732a973
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-slc6a8'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

16

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SLC6A8 Gene

SLC6A8 Gene

Overview

SLC6A8 Gene

Overview

Gene And Protein Architecture

Transport Mechanism

Physiologic Role In Energy Metabolism

The Phosphocreatine System

Brain Energy Metabolism

SLC6A8 In Neurodegeneration

Creatine Deficiency Syndrome (CDS)

Female Carriers

Pathophysiology

Therapeutic Implications

Clinical Genetics

Variant Spectrum

Inheritance Pattern

Genotype-Phenotype Correlation

Structural Biology

SLC6 Family Comparison

Inhibitors and Substrates

Biomarker Relevance

Diagnostic Biomarkers

Monitoring

Animal Models

Mouse Models

Zebrafish Models

Therapeutic Development

Current Management

Emerging Therapies

Clinical Trials

Research Tools

Functional Assays

In Vitro Systems

Summary

See Also

External Links

Allen Brain Atlas

References

💬 Discussion